Catamaran Bio Inc.

Fate’s pipeline reprioritization raises questions about iPSC-derived NK cells

BioCentury’s roundup of translational news

Plus Turtle leaving BridgeBio, and updates from Clover, Y-mAbs, Genenta and more

Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

Plus Singleton to join Bioventus as CFO, and updates from Noema, Lycia, Avidity and more

HHS named Erica Jefferson FDA associate commissioner for external affairs. Jefferson served as a spokesperson and acting assistant commissioner for media affairs at the agency during the Obama

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) promoted Osamu Okuda to CEO from president and COO, succeeding Tatsuro Kosaka who will remain chairman. Okuda, who joined Chugai in 1987, has served as

A snapshot of the next iteration of gene and cell therapies, gene editors, protein degraders and more

How Catamaran is designing off-the-shelf CAR NK cells to broaden the reach of cell therapies